Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial

CheckMate -901 is the first and only Phase 3 trial with an immunotherapy-based combination to demonstrate a survival benefit compared to standard-of-care cisplatin-based combinations in the first-line treatment of this patient population

Related Keywords

Japan ,Taiwan ,South Korea ,United States ,China ,Bristol Myers Squibb ,Dana Walker ,Linkedin ,Facebook ,Youtube ,Exchange Commission ,Instagram ,Ono Pharmaceutical Co ,Company Opdivo ,Twitter ,European Union ,Blinded Independent Central Review ,Bristol Myers ,Myers Squibb ,Better Future ,Fatal Immune Mediated Adverse ,Full Prescribing Information ,Allogeneic Hematopoietic Stem Cell ,Multiple Myeloma ,Thalidomide Analogue ,Prescribing Information ,Ono Pharmaceutical ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,